Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

NCT01187953 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

543

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Failure

Interventions

DRUG: Prograf (tacrolimus)
DRUG: LCP-Tacro

Sponsor

Veloxis Pharmaceuticals